NCT03708523

Brief Summary

This study tried to highlight the predictive value of the morning postoperative cortisol levels, which can act as the prognosis value of the postoperative pituitary function, providing future medication advices for improving patients' safety of drugs.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 14, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 17, 2018

Completed
15 days until next milestone

Study Start

First participant enrolled

November 1, 2018

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

October 17, 2018

Status Verified

October 1, 2018

Enrollment Period

10 months

First QC Date

October 14, 2018

Last Update Submit

October 14, 2018

Conditions

Hypopituitarism

Keywords

Hypopituitarism,Pituitary function

Outcome Measures

Primary Outcomes (1)

  • Next Day Early Morning Growth Hormone as Predictor of Pituitary Function After Transsphenoidal Adenomectomy

    To predict the morning postoperative cortisol levels, for further prediction of the postoperative pituitary function.

    2 days

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who had been treated with TSA were enrolled.

You may qualify if:

  • Patients who had been treated with TSA were enrolled.

You may not qualify if:

  • Hypopituitarism preoperatively.
  • Acromegaly
  • Multiple operations
  • Incomplete hormone data or loss of follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, 100, Taiwan

Location

MeSH Terms

Conditions

Hypopituitarism

Condition Hierarchy (Ancestors)

Pituitary DiseasesHypothalamic DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEndocrine System Diseases

Study Officials

  • Fon-Yih Tsuang, MD

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fon-Yih Tsuang

CONTACT

0972651142tsuangfy@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 14, 2018

First Posted

October 17, 2018

Study Start

November 1, 2018

Primary Completion

September 1, 2019

Study Completion

September 1, 2019

Last Updated

October 17, 2018

Record last verified: 2018-10

Locations

TW(1)